MNMD insider transaction filings
Mind Medicine (MindMed) Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-12-29. Screen MNMD transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for MNMD between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Mind Medicine (MindMed) Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-12-29 | 4 | Karlin Daniel — Chief Medical Officer | Sale (S): 5,600 @ $13.15 | EDGAR |
| 2025-12-29 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 25,791 @ $13.15 | EDGAR |
| 2025-12-29 | 4 | Sullivan Mark — Chief Legal Officer | Sale (S): 11,276 @ $13.15 | EDGAR |
| 2025-09-26 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 25,797 @ $9.77 | EDGAR |
| 2025-09-26 | 4 | Karlin Daniel — Chief Medical Officer | Sale (S): 7,704 @ $9.77 | EDGAR |
| 2025-09-26 | 4 | Sullivan Mark — Chief Legal Officer | Sale (S): 11,278 @ $9.77 | EDGAR |
| 2025-06-26 | 4 | Karlin Daniel — Chief Medical Officer | Sale (S): 7,848 @ $6.80 | EDGAR |
| 2025-06-26 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 26,491 @ $6.80 | EDGAR |
| 2025-06-26 | 4 | Sullivan Mark — Chief Legal Officer | Sale (S): 11,491 @ $6.80 | EDGAR |
| 2025-06-16 | 4 | CRYSTAL ROGER — Director | Grant/award (A): 75,187 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Bruhn Suzanne Louise — Director | Grant/award (A): 75,187 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Krebs Andreas — Director | Grant/award (A): 75,187 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Vallone Carol A — Director | Grant/award (A): 75,187 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | GRYSKA DAVID W — Director | Grant/award (A): 75,187 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Roberts Brandi — Chief Financial Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 21,208 @ $6.74 | EDGAR |
| 2025-03-26 | 4 | Karlin Daniel — Chief Medical Officer | Sale (S): 6,836 @ $6.74 | EDGAR |
| 2025-03-26 | 4 | Liao Carrie — Chief Accounting Officer | Sale (S): 2,347 @ $6.74 | EDGAR |
| 2025-03-26 | 4 | Sullivan Mark — Chief Legal Officer | Sale (S): 6,576 @ $6.74 | EDGAR |
| 2025-03-18 | 4 | Wiley Matthew T. — Chief Commercial Officer | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | Barrow Robert — Chief Executive Officer, Director | Grant/award (A): 350,000 @ $0 | EDGAR |
| 2025-03-13 | 4 | Karlin Daniel — Chief Medical Officer | Grant/award (A): 115,000 @ $0 | EDGAR |
| 2025-03-13 | 4 | Liao Carrie — Chief Accounting Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-03-13 | 4 | Sullivan Mark — Chief Legal Officer | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2024-12-27 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 19,106 @ $7.43 | EDGAR |
| 2024-12-27 | 4 | Liao Carrie — Chief Accounting Officer | Sale (S): 2,273 @ $7.43 | EDGAR |
| 2024-12-27 | 4 | Karlin Dan — Chief Medical Officer | Sale (S): 6,643 @ $7.43 | EDGAR |
| 2024-12-27 | 4 | Sullivan Mark — Chief Legal Officer | Sale (S): 4,519 @ $7.43 | EDGAR |
| 2024-12-05 | 4 | GRYSKA DAVID W — Director | Purchase (P): 2,500 @ $7.17 | EDGAR |
| 2024-09-25 | 4 | Liao Carrie — Chief Accounting Officer | Sale (S): 2,352 @ $5.98 | EDGAR |
| 2024-09-25 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 19,771 @ $5.98 | EDGAR |
| 2024-09-25 | 4 | Karlin Dan — Chief Medical Officer | Sale (S): 6,871 @ $5.98 | EDGAR |
| 2024-09-25 | 4 | Sullivan Mark — Chief Legal Officer | Sale (S): 4,430 @ $5.98 | EDGAR |
| 2024-08-26 | 4 | GRYSKA DAVID W — Director | Purchase (P): 3,500 @ $5.98 | EDGAR |
| 2024-08-22 | 4 | Halperin Wernli Miri — Executive President | Option exercise (M): 50,000 @ $3.70 · Tax withholding (F): 32,595 @ $6.17 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2024-08-20 | 4 | Barrow Robert — Chief Executive Officer, Director | Purchase (P): 500 @ $6.31 · Purchase (P): 500 @ $6.12 | EDGAR |
| 2024-06-25 | 4 | Karlin Dan — Chief Medical Officer | Sale (S): 6,925 @ $7.22 | EDGAR |
| 2024-06-25 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 15,659 @ $7.22 | EDGAR |
| 2024-06-25 | 4 | Sullivan Mark — Chief Legal Officer | Sale (S): 17,854 @ $7.22 | EDGAR |
| 2024-06-12 | 4 | CRYSTAL ROGER — Director | Grant/award (A): 16,506 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Bruhn Suzanne Louise — Director | Grant/award (A): 16,506 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Krebs Andreas — Director | Grant/award (A): 16,506 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Vallone Carol A — Director | Grant/award (A): 16,506 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | GRYSKA DAVID W — Director | Grant/award (A): 16,506 (derivative) @ $0 | EDGAR |
| 2024-03-26 | 4 | Greenway Schond L. — Chief Financial Officer | Tax withholding (F): 5,560 @ $9.78 | EDGAR |
| 2024-03-26 | 4 | Karlin Dan — Chief Medical Officer | Sale (S): 6,578 @ $9.50 | EDGAR |
| 2024-03-26 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 16,519 @ $9.50 | EDGAR |
| 2024-02-29 | 4 | Barrow Robert — Chief Executive Officer, Director | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | Karlin Dan — Chief Medical Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | Sullivan Mark — Chief Legal Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Mind Medicine (MindMed) Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MNMD returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →